JENBURKT PHARMACEUTICALS Financial Statement Analysis
|
||
The Revenues of JENBURKT PHARMACEUTICALS have increased by 6.85% YoY .
The Earnings Per Share (EPS) of JENBURKT PHARMACEUTICALS has increased by 23.43 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
JENBURKT PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 524731]
Standalone | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
---|---|---|---|---|---|
Revenues | ₹152 Cr | ₹142 Cr | ₹137 Cr | ₹124 Cr | ₹109 Cr |
Expenses | ₹111 Cr | ₹109 Cr | ₹106 Cr | ₹97 Cr | ₹89 Cr |
Operating Profit (Excl OI) | ₹40 Cr | ₹33 Cr | ₹30 Cr | ₹27 Cr | ₹20 Cr |
Other Income | ₹6.72 Cr | ₹4.67 Cr | ₹5.12 Cr | ₹4.95 Cr | ₹4.31 Cr |
Interest | ₹0.45 Cr | ₹0.27 Cr | ₹0.37 Cr | ₹0.43 Cr | ₹0.47 Cr |
Depreciation | ₹2.73 Cr | ₹2.34 Cr | ₹2.26 Cr | ₹1.90 Cr | ₹2.04 Cr |
Profit Before Tax | ₹44 Cr | ₹35 Cr | ₹33 Cr | ₹30 Cr | ₹22 Cr |
Profit After Tax | ₹32 Cr | ₹26 Cr | ₹25 Cr | ₹22 Cr | ₹17 Cr |
Earnings Per Share (Rs) | ₹72.65 | ₹58.86 | ₹55.76 | ₹48.58 | ₹35.96 |
PAT Margin (%) | 21.14 | 18.30 | 17.99 | 17.98 | 15.10 |
ROE(%) | 20.25 | 19.43 | 20.53 | 20.66 | 18.49 |
ROCE(%) | 27.85 | 26.28 | 26.80 | 26.89 | 23.83 |
Total Debt/Equity(x) | 0.01 | 0.00 | 0.02 | 0.05 | 0.04 |
Key Financials |
||
Market Cap | : | ₹ 603.7 Cr |
Revenue (TTM) | : | ₹ 151.7 Cr |
Net Profit(TTM) | : | ₹ 32.1 Cr |
EPS (TTM) | : | ₹ 72.9 |
P/E (TTM) | : | 18.8 |
Industry Peers & Returns | 1W | 1M | 1Y |
JENBURKT PHARMACEUTICALS | 5.6% | 21% | 46.6% |
SUN PHARMACEUTICAL INDUSTRIES | 0.9% | -0.1% | 10.9% |
DIVIS LABORATORIES | 3.7% | 3% | 46.5% |
CIPLA | 0.2% | 2.8% | 1.6% |
TORRENT PHARMACEUTICALS | 7.3% | 7.4% | 19.8% |
DR REDDYS LABORATORIES | -4% | 2.6% | 7.2% |
MANKIND PHARMA | 0.6% | -6.1% | 9.3% |
ZYDUS LIFESCIENCES | 2.6% | 6.4% | -8% |
LUPIN | 0.4% | -1.1% | 22.2% |
JENBURKT PHARMACEUTICALS Revenues
[BOM: 524731]
Y-o-Y | 6.85 % |
5 Yr CAGR | 8.54 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹152 Cr | 6.85 | |
Mar2024 | ₹142 Cr | 3.82 | |
Mar2023 | ₹137 Cr | 10.30 | |
Mar2022 | ₹124 Cr | 13.44 | |
Mar2021 | ₹109 Cr | - |
JENBURKT PHARMACEUTICALS Operating Profit
[BOM: 524731]
Y-o-Y | 21.96 % |
5 Yr CAGR | 19.45 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹40 Cr | 21.96 | |
Mar2024 | ₹33 Cr | 9.06 | |
Mar2023 | ₹30 Cr | 11.42 | |
Mar2022 | ₹27 Cr | 37.36 | |
Mar2021 | ₹20 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 14.14 % |
5 Yr CAGR | 10.06 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 26.63% | 14.14 | |
Mar2024 | 23.33% | 5.04 | |
Mar2023 | 22.21% | 1.05 | |
Mar2022 | 21.98% | 21.10 | |
Mar2021 | 18.15% | - |
JENBURKT PHARMACEUTICALS Profit After Tax
[BOM: 524731]
Y-o-Y | 23.42 % |
5 Yr CAGR | 18.06 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹32 Cr | 23.42 | |
Mar2024 | ₹26 Cr | 5.57 | |
Mar2023 | ₹25 Cr | 10.36 | |
Mar2022 | ₹22 Cr | 35.12 | |
Mar2021 | ₹17 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 15.52 % |
5 Yr CAGR | 8.78 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 21.14 % | 15.52 | |
Mar2024 | 18.3 % | 1.72 | |
Mar2023 | 17.99 % | 0.06 | |
Mar2022 | 17.98 % | 19.07 | |
Mar2021 | 15.1 % | - |
JENBURKT PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 524731]
Y-o-Y | 23.43 % |
5 Yr CAGR | 19.22 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹73 | 23.43 | |
Mar2024 | ₹59 | 5.56 | |
Mar2023 | ₹56 | 14.78 | |
Mar2022 | ₹49 | 35.09 | |
Mar2021 | ₹36 | - |
JENBURKT PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 524731]
Y-o-Y | 5.97 % |
5 Yr CAGR | 3.97 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2025 | 27.85% | 5.97 | |
Mar2024 | 26.28% | -1.94 | |
Mar2023 | 26.8% | -0.33 | |
Mar2022 | 26.89% | 12.84 | |
Mar2021 | 23.83% | - |
JENBURKT PHARMACEUTICALS Share Price vs Sensex
Current Share Price | : | ₹1,372.1 |
Current MarketCap | : | ₹ 603.7 Cr |
Updated EOD on | : | Jun 30,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
JENBURKT PHARMACEUTICALS | 5.6% |
21% |
46.6% |
SENSEX | 2.1% |
2.4% |
7.1% |
JENBURKT PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about JENBURKT PHARMACEUTICALS Financials
How the annual revenues of JENBURKT PHARMACEUTICALS have changed ?
The Revenues of JENBURKT PHARMACEUTICALS have increased by 6.85% YoY .
How the Earnings per Share (EPS) of JENBURKT PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of JENBURKT PHARMACEUTICALS has increased by 23.43 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs